An introduction to current standards of CARE in invasive fungal disease

DOI: 10.1093/jac/dkz036

Document Version
Accepted author manuscript

Citation for published version (APA):

Published in:
Journal of Antimicrobial Chemotherapy

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Invasive fungal infections are life-threatening conditions that require rapid diagnosis and optimal management to alleviate their high morbidity and mortality. They are also associated with a high economic burden, owing to prolonged hospitalisation, the need for intensive supportive care, and the consumption of costly new antifungal agents. Many standards of care and guidelines have been published by national and international medical societies and organisations over the past 20 years which have embraced new diagnostic technologies and strategies, and new antifungal drugs. Recognising the ongoing need and debate on the topic of standards for optimal diagnostics and patient care, the Scientific Committee of the Continuing Antifungal Research and Education (CARE) programme devised the scientific agenda for the 10th CARE (CARE X) meeting to review current practice and recommendations. Specialists in haematology, infectious diseases, medical microbiology and medical mycology met in Barcelona in November 2017. The meeting was organised and funded by Gilead Sciences Europe Ltd.

What is a standard of care? An appropriate definition in the medical context is the watchfulness, attention, caution and prudence that a reasonable person, a team or
organisation, such as a national medical society would exercise. In the clinical mycology context, a standard of care means the optimal degree of care and skill of the specialist healthcare provider who practices the specialty, taking into account the medical knowledge that is available to the clinician. In the context of guidelines, a further definition could be evidence-supported investigations and interventions delivered in a timely and logical fashion to reduce the risk of developing invasive fungal disease (IFD) or reducing the morbidity and mortality from IFD. That specialist knowledge can be provided through a number of educational channels including the information and guidance provided in this supplement of the *Journal of Antimicrobial Chemotherapy*. The reviews reflect a cross-section of best laboratory clinical practice from leading hospitals across Europe.

The articles presented here provide a series of key recommendations for the appropriate use of mycological, immunological and radiological diagnostic methods for the diagnosis of invasive fungal diseases. The recommendations emphasise the role of immunoassays and biomarker quantification as exemplars of rapid diagnostic tests to guide treatment decisions. In this Supplement, we provide information to improve understanding of the importance of fungal diagnostics for invasive fungal infection, fungal infections that occur in the intensive care unit, in solid organ transplant recipients, and in haematology patients. What is the current treatment best practice for diseases such as aspergillosis and candidosis? The antifungal armamentarium is small but there are now at least seven new antifungal molecules in clinical trials and many more at various stages of development. The new antifungal landscape is reviewed here.

**TRANSPARENCY DECLARATION:**
MDR has been an advisor and lecturer for Gilead Sciences, MSD, Basilea, and Pfizer.
MCE has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp & Dohme, Pfizer, Schering Plough, CIDARA, Amplyx, F2G, Scynexis, Soria Melguizo SA, and Ferrer International.
JM served as consultant to Gilead Sciences, Merck, Sharp & Dohme, Pfizer Inc., Astellas, Basilea Pharmaceutica, F2G, Cidara, Amplyx, Scynexis, Vical, Bio-Rad, Fujisawa Healthcare, Inc., Zeneus (Cephalon), Viropharma, Boehringer-Ingelheim, Amgen, Cellgene and Shire; has been on speakers bureaus for Gilead Sciences, Merck, Sharp & Dohme, Pfizer Inc., Basilea Pharmaceutica, Bio-Rad, Fujisawa Healthcare, Inc, Astellas Pharma, and Zeneus (Cephalon);
received research funding from Bio-Rad, Merck, Sharp & Dohme, Gilead Sciences, and Pfizer Inc.

This article forms part of a Supplement sponsored and funded by Gilead Sciences; Tribal Healthcare provided editorial assistance. The content of this Supplement is based on the sessions presented at the CARE X meeting, held in Barcelona in November 2017.